Synthetic Immune Receptor T (SIR-T) Cells Targeting B7-H3 for the Treatment of Renal Cancer
Abstract
Patients with kidney cancer show high-level expression of a protein called B7-H3. Chimeric antigen receptor T (CAR-T) is a novel approach to genetically engineer immune cells to kill cancer cells. Despite the success of CAR-T in blood cancers, there are several limitations to this approach including lack of efficacy against solid tumor and toxicities. To overcome the above design limitations of the current generation CARs, we have developed a next-generation platform, designated SIR (Synthetic Immune Receptor). The main objective of the proposal is to generate a panel of SIRs targeting B7-H3 for the treatment of kidney cancers and to demonstrate their efficacy and safety using preclinical studies. Thus, the project s area of emphasis is to identify innovative strategies for the treatment of kidney cancer. At the end of the project period, we hope to have obtained evidence of safety and efficacy of B7-H3 SIR using preclinical studies that will lay the foundation for confirmatory studies before the initiation of human clinical trials in 4-5 years. In the long term, the B7-H3 SIR developed by this project could potentially revolutionize the treatment of kidney cancers as a single injection of B7-H3 SIR could potentially result in long-term remission and perhaps cure of even advance metastatic disease. The B7-H3 SIR of the current proposals could also be combined with other forms of immunotherapy and/or targeted therapies to further improve the response rate or duration of remission. The project is highly relevant to military health as military personnel are at high risk of kidney cancer due to high prevalence of smoking among Service Members and their exposure to environmental toxins.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Jan 04, 2024
- Source ID
- HT94252311005
Entities
People
- Preet Chaudhary
Organizations
- United States Army
- University of Southern California